Does USTEKINUMAB Cause Neoplasm malignant? 373 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 373 reports of Neoplasm malignant have been filed in association with USTEKINUMAB (PYZCHIVA). This represents 0.4% of all adverse event reports for USTEKINUMAB.
373
Reports of Neoplasm malignant with USTEKINUMAB
0.4%
of all USTEKINUMAB reports
27
Deaths
49
Hospitalizations
How Dangerous Is Neoplasm malignant From USTEKINUMAB?
Of the 373 reports, 27 (7.2%) resulted in death, 49 (13.1%) required hospitalization, and 23 (6.2%) were considered life-threatening.
Is Neoplasm malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for USTEKINUMAB. However, 373 reports have been filed with the FAERS database.
What Other Side Effects Does USTEKINUMAB Cause?
Drug ineffective (12,471)
Off label use (10,990)
Product dose omission issue (9,405)
Fatigue (5,457)
Product use issue (5,008)
Psoriasis (4,955)
Pain (4,872)
Rash (4,736)
Crohn's disease (4,662)
Arthralgia (4,608)
What Other Drugs Cause Neoplasm malignant?
RANITIDINE (10,648)
ADALIMUMAB (2,028)
APIXABAN (1,772)
ETANERCEPT (1,616)
METHOTREXATE (1,041)
TOFACITINIB (1,020)
RITUXIMAB (929)
INFLIXIMAB (892)
ABATACEPT (727)
RISANKIZUMAB-RZAA (715)
Which USTEKINUMAB Alternatives Have Lower Neoplasm malignant Risk?
USTEKINUMAB vs USTEKINUMAB-STBA
USTEKINUMAB vs VADADUSTAT
USTEKINUMAB vs VALACYCLOVIR
USTEKINUMAB vs VALBENAZINE
USTEKINUMAB vs VALBENAZINE DITOSYLATE